Creative Medical Technology (NASDAQ: CELZ) has secured a Notice of Allowance from the USPTO for a patent covering its ImmCelz™ therapy targeting heart failure and post-infarction pathological remodeling. The patent protection extends until at least 2040 for the company’s proprietary therapy, administered via minimally invasive outpatient procedures.
The addressable patient population exceeds 11 million in the U.S., including over 5 million heart failure patients and approximately 6 million chronic chest pain sufferers. This development significantly expands Creative Medical’s intellectual property foothold in regenerative medicine.
Positive
- Patent protection secured until at least 2040 for ImmCelz treatment
- Large addressable market of over 11 million potential patients in the US
- Treatment delivered through ultra-minimally invasive outpatient procedure
- Strengthens company’s intellectual property portfolio in regenerative medicine
Negative
- Product remains in clinical development, without FDA approval
- No current revenue generation from this treatment
07/11/2025 – 08:01 AM
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) — Clinical-stage biotech firm Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.”
The patent, enforceable until at least 2040, protects the company’s ImmCelz therapeutic approach for preventing and treating heart failure. The technology specifically targets post-infarction pathological remodeling—a process where heart muscle undergoes deleterious structural changes following heart attacks, often culminating in cardiac dysfunction.
With over 5 million heart failure patients in the U.S. and an additional 6 million suffering refractory angina, the therapy’s potential market exceeds 11 million patients. ImmCelz is delivered through an outpatient procedure requiring minimal intervention.
“This allowance reinforces our leadership in cellular reprogramming technologies,” stated CEO Timothy Warbington. “It strategically extends our intellectual property runway in regenerative medicine while validating our platform’s potential across multiple therapeutic areas.”
ImmCelz Platform Mechanics
The ImmCelz platform reprograms a patient’s immune cells outside the body using proprietary cell-free factors. These “supercharged” cells are reintroduced to potentially enhance tissue regeneration while performing native immune functions.
Creative Medical Technology Holdings
Creative Medical Technology (NASDAQ: CELZ) develops regenerative therapies targeting neurological disorders, urological conditions, and pain management through advanced cellular platforms.
Forward-Looking Statements
Certain statements contained herein constitute forward-looking predictions regarding therapeutic potential and intellectual property strategy. Actual results may materially differ due to clinical, regulatory, and market variables. Detailed risk disclosures are available in SEC filings.
FAQ
What patent protection did Creative Medical secure?
CELZ received USPTO allowance for patent protection until 2040 covering ImmCelz treatment of heart failure and post-infarction heart remodeling.
How large is the potential market for ImmCelz?
The therapy addresses over 11 million U.S. patients including 5 million heart failure sufferers and 6 million chronic chest pain patients.
How is ImmCelz administered?
The treatment utilizes an ultra-minimally invasive outpatient procedure.
What conditions does the patent cover?
It includes heart failure and pathological heart remodeling after heart attacks, both preventative and therapeutic applications.
Is ImmCelz commercially available?
The therapy remains in clinical development without current FDA approval or commercialization.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/4514.html
